Article Information
- July 12, 2024.
Article Versions
- Version 1 (February 20, 2024 - 10:36).
- You are viewing Version 2, the most recent version of this article.
REVISION SUMMARY
Several changes implemented in response to peer-review comments including: (i) significantly reduced word count (particularly in the discussion section), (ii) replaced two results subsections with more pertinent ones (i.e., sections addressing the potential for horizontal pleiotropy, novelty, and drugability), and (iii) added an ideogram as a main figure showing the distribution of the 61 'validated' schizophrenia-associated genes.
Author Information
- David Stacey, PhD1,2,3,*,
- Liam Gaziano, PhD4,
- Preethi Eldi, PhD2,
- Catherine Toben, PhD5,
- Beben Benyamin, PhD1,3,6,
- S Hong Lee, PhD1,3,6 and
- Elina Hyppönen, PhD1,2,3
- 1Australian Centre for Precision Health, University of South Australia, Adelaide, South Australia, Australia
- 2UniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia
- 3South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia
- 4Harvard Medical School, Boston, Massachusetts, USA
- 5University of Adelaide, Discipline of Psychiatry, Adelaide, South Australia, Australia
- 6UniSA Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia
- ↵*Corresponding author Dr. David Stacey, Postal address: South Australian Health and Medical Research Institute (SAHMRI), level 8 south, North Terrace, Adelaide, SA 5000, Australia. E-mail: david.stacey{at}unisa.edu.au, Tel: +61 (0)8 8302 8339